NasdaqGM:OCULPharmaceuticals
How Axpaxli Phase 3 Anticipation from Key Ophthalmology Meetings Will Impact Ocular Therapeutix (OCUL) Investors
Ocular Therapeutix recently highlighted its retinal pipeline at major ophthalmology meetings, where senior leaders discussed managing neovascular age-related macular degeneration and the role of tyrosine kinase inhibitors in treating diabetic retinal disease.
Investors are closely watching these conference appearances for fresh colour on the phase 3 Axpaxli program, which sits at the centre of the company’s long-term growth plans.
We’ll now explore how anticipated Axpaxli phase 3 updates...